Evidence map›Paper›PMID 41494789›Full record

ArticleKorean journal of radiology2026

Response to Comments on "Pretreatment [⁶⁸Ga]-PSMA-11 PET/CT to Predict the Response to Treatment With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma".

Shao-Hao Chen, Xiao-Hui Wu, Qian-Ren-Shun Qiu, Shao-Ming Chen, Jie Zang, Jun-Ming Zhu, Cheng-Long Zeng, Wei-Bing Miao, Xue-Yi Xue, Ning Xu

Abstract readLetter
In one paragraph

Article in Korean journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Shao-Hao Chen *Department of Urology, Urology Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0000-0002-7243-4428
Xiao-Hui Wu *Department of Urology, Urology Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0000-0002-8916-9237
Qian-Ren-Shun QiuDepartment of Urology, Urology Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0009-0004-5403-4502
Shao-Ming ChenDepartment of Nuclear Medicine, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0000-0001-9946-2077
Jie ZangDepartment of Nuclear Medicine, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0009-0002-8281-9177
Jun-Ming ZhuDepartment of Urology, Urology Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0000-0002-7389-432X
Cheng-Long ZengDepartment of Urology, Urology Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0009-0000-6024-1752
Wei-Bing MiaoDepartment of Nuclear Medicine, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0000-0002-0058-4953
Xue-Yi XueDepartment of Urology, Urology Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0000-0002-6461-7435
Ning XuDepartment of Urology, Urology Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0000-0001-7909-7025

Funding

Class B Talent Research Project of the First Affiliated Hospital of Fujian Medical University YJCRC-B-XN2022"Eyas Plan" Youth Top-notch Talent Project of Fujian Province SCYJHBJRC-XN2021
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immune checkpoint inhibitorsMetastatic renal cell carcinomaPSMA PET/CTTyrosine kinase inhibitors

Identifiers

PMID41494789
PMCPMC12865109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.